Latest Healthcare News

Vectus Biosystems has reported a striking turnaround with a $1.56 million profit for the 2026 financial year, reversing a prior year loss and improving its balance sheet significantly.

Nuchev has inked a consignment-based distribution deal to launch the Kuci women’s health probiotic range nationally through Chemist Warehouse, marking a strategic expansion into women’s health.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

Kyron Capital Group (ASX: KYN) reported a $51.9 million net loss for FY26, completing a $125 million recapitalisation to stabilise its balance sheet and reduce gearing. The Group's assets under management shrank to $1.8 billion following strategic divestments and mandate exits.

Micro-X Limited lifted revenues by 16% to $15.1 million for FY26 but posted a $9.9 million net loss, narrowing from the prior year. The company advanced key medical imaging milestones and initiated a strategic reset to sharpen commercial focus and reduce costs.

Australian Foundation Investment Company (ASX:AFI) reported a $293.5 million profit for FY26, holding dividends steady despite portfolio returns lagging the market. Leadership transitioned as Alison Gibson took the helm following Mark Freeman’s retirement.

Constellation Technologies (ASX:CT1) reported a 5% revenue decline to $1.71 million and a $458,246 net loss for FY26, weighed down by delayed hardware deployments and increased expenses. Recurring subscription revenue grew 22%, reflecting ongoing customer engagement.

IMEXHS Limited has swung to a profit of $66,200 in 1H FY26, driven by a 17% revenue increase and a surge in underlying EBITDA to $1.27 million. The company’s AI-native radiology platform and Latin American partner expansion underpin growth amid ongoing sector liquidity challenges.

Cobram Estate Olives (ASX:CBO) posted an 11.3% revenue increase to A$268.9 million in FY2026 but swung to a A$4.2 million net loss as costs surged and integration expenses weighed. The company declared a steady fully franked dividend of 4.5 cents per share.

Resonance Health (ASX: RHT) reported a profitable turnaround in FY26, driven by growth across its imaging software, clinical trial services, and site network businesses.

Memphasys has secured early Thai FDA approval for its Felix™ System, triggering a three-year exclusive distribution deal with IVF Envimed and prompting additional orders amid strong clinic interest.